Unlocking ROI And Efficiency In Drug Development

How much value does service integration actually create? Research from the Tufts Center for the Study of Drug Development offers a data-driven answer, modeling the financial and operational impact of consolidating manufacturing, clinical research, laboratory, and supply chain services under a single provider across oncology programs.

Using real-world clinical trial data and industry benchmarks, the analysis quantified outcomes across both monoclonal antibodies and small molecules, measuring projected eNPV gains, ROI, and phase duration reductions under multiple integration scenarios. The findings show consistent benefits regardless of phase or modality, with up to 34 months saved through coordinated execution and up to $16.4M in eNPV gains for Phase 2 and Phase 3 programs.

Explore the research to see how integration scenarios compare across your programs.